The news is directly about Neurocrine Biosciences. Mizuho's decision to maintain a Neutral rating indicates that they do not expect significant price movement in the short term. However, the slight increase in the price target could be seen as a positive signal, but it's unlikely to have a major impact on the stock's price in the short term.